Risedronate, an oral bisphosphonate, is prescribed for severe postmenopausal osteoporosis. Which biological…
From Medical Nursing · Metabolic Bone Disorders Pharmacology · Written by Isaac Agyapong (Tutor)
Risedronate, an oral bisphosphonate, is prescribed for severe postmenopausal osteoporosis. Which biological marker is the primary target inhibited by this class of medication?
- A. The total complete breakdown and destruction of all of the insulin hormone stored within the specialized beta cells located inside the islets of the patient's pancreas gland.
- B. The completely healthy, normal, and physiologically routine ongoing production of new circulating red blood cells occurring deep within the patient's enlarged splenic tissue.
- C. Osteoclast activity, thereby reducing bone resorption and slowing down the rate of bone loss.
Sign in and answer this question to see the correct answer and the explanation.